Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of ABX464 25 mg once daily in moderate to severe ulcerative colitis
2021-004398-30Phase 2Active
- Sponsor
- Abivax
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obefazimod in autoimmune colitis, sponsored by Abivax. Primary endpoint: Number of adverse events in ABX464 treated subjects. Started Oct 2021; status: active.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2021-004398-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004398-30.